A randomized, double-blind, placebo-controlled study of Gelesis100: A novel nonsystemic oral hydrogel for weight loss

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt


  • Frank L Greenway
  • Louis J Aronne
  • Arne Astrup
  • Caroline M Apovian
  • James O Hill
  • Lee M Kaplan
  • Ken Fujioka
  • Erika Matejkova
  • Stepan Svacina
  • Livio Luzi
  • Lucio Gnessi
  • Santiago Navas-Carretero
  • J Alfredo Martinez
  • Christopher D Still
  • Alessandro Sannino
  • Cosimo Saponaro
  • Christian Demitri
  • Lorien E Urban
  • Harry Leider
  • Elaine Chiquette
  • Eyal S Ron
  • Yishai Zohar
  • Hassan M Heshmati

Objective: This study aims to assess the efficacy and safety of Gelesis100, a novel, nonsystemic, superabsorbent hydrogel to treat overweight or obesity.

Methods: The Gelesis Loss Of Weight (GLOW) study was a 24-week, multicenter, randomized, double-blind, placebo-controlled study in patients with BMI ≥  27 and ≤ 40 kg/m2 and fasting plasma glucose ≥ 90 and ≤ 145 mg/dL. The co-primary end points were placebo-adjusted weight loss (superiority and 3% margin super-superiority) and at least 35% of patients in the Gelesis100 group achieving ≥ 5% weight loss.

Results: Gelesis100 treatment caused greater weight loss over placebo (6.4% vs. 4.4%, P = 0.0007), achieving 2.1% superiority but not 3% super-superiority. Importantly, 59% of Gelesis100-treated patients achieved weight loss of ≥ 5%, and 27% achieved ≥ 10% versus 42% and 15% in the placebo group, respectively. Gelesis100-treated patients had twice the odds of achieving ≥ 5% and ≥ 10% weight loss versus placebo (adjusted OR: 2.0, P = 0.0008; OR: 2.1, P = 0.0107, respectively), with 5% responders having a mean weight loss of 10.2%. Patients with prediabetes or drug-naive type 2 diabetes had six times the odds of achieving ≥ 10% weight loss. Gelesis100 treatment had no apparent increased safety risks.

Conclusions: Gelesis100 is a promising new nonsystemic therapy for overweight and obesity with a highly desirable safety and tolerability profile.

Udgave nummer2
Sider (fra-til)205-216
Antal sider12
StatusUdgivet - 2019

Bibliografisk note

CURIS 2019 NEXS 042

Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk

Ingen data tilgængelig

ID: 208905561